Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ: RARE · IEX Real-Time Price · USD

42.55

-0.23 (-0.54%)

At close: Jul 19, 2024, 4:00 PM

42.37

-0.18 (-0.42%)

Pre-market: Jul 22, 2024, 8:54 AM EDT

Ultragenyx Pharmaceutical Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2012
Cash & Equivalents	112.25	213.58	132.94	307.58	713.53	433.58	Upgrade
Short-Term Investments	299.83	363.63	614.82	432.61	488.01	321.65	Upgrade
Cash & Cash Equivalents	412.08	577.21	747.76	740.2	1,202	755.23	Upgrade
Cash Growth	-34.52%	-22.81%	1.02%	-38.40%	59.09%	64.29%	Upgrade
Receivables	100.25	73.39	40.45	28.43	23.09	32.84	Upgrade
Inventory	35.91	33.97	26.77	16.23	13.05	11.55	Upgrade
Other Current Assets	47.73	47.62	68.93	71.75	57.63	51.4	Upgrade
Total Current Assets	595.97	732.18	883.9	856.6	1,295	851.02	Upgrade
Property, Plant & Equipment	285.11	290.57	259.73	176.18	114.04	74.68	Upgrade
Long-Term Investments	156.58	199.9	148.97	293.86	165.88	32.93	Upgrade
Goodwill and Intangibles	209.45	210.68	204.51	175.19	175.52	173.41	Upgrade
Other Long-Term Assets	59.97	57.69	48.34	20.56	8.81	3.47	Upgrade
Total Long-Term Assets	711.11	758.83	661.55	665.79	464.25	284.48	Upgrade
Total Assets	1,307	1,491	1,545	1,522	1,760	1,135	Upgrade
Accounts Payable	40.97	42.11	43.27	17.14	12.92	12.87	Upgrade
Deferred Revenue	0	0	1.48	9.08	66.57	0	Upgrade
Current Debt	12.78	12.6	11.78	11.07	8.98	7.24	Upgrade
Other Current Liabilities	191.82	225.73	204.68	144.09	101.14	83.19	Upgrade
Total Current Liabilities	245.58	280.44	261.21	181.37	189.61	103.3	Upgrade
Long-Term Debt	27.98	30.57	19.81	30.9	39.25	29.76	Upgrade
Other Long-Term Liabilities	893.26	904.59	911.93	387.56	376.32	348.68	Upgrade
Total Long-Term Liabilities	921.24	935.16	931.74	418.47	415.57	378.43	Upgrade
Total Liabilities	1,167	1,216	1,193	599.84	605.18	481.73	Upgrade
Total Debt	40.76	43.17	31.59	41.97	48.23	36.99	Upgrade
Debt Growth	42.51%	36.64%	-24.72%	-12.97%	30.37%	-	Upgrade
Retained Earnings	-3,558.35	-3,387.66	-2,781.02	-2,073.6	-1,619.58	-1,433.01	Upgrade
Comprehensive Income	-0.43	0.65	-6.57	-1.4	0.69	-0.15	Upgrade
Shareholders' Equity	140.26	275.41	352.49	922.56	1,154	653.76	Upgrade
Net Cash / Debt	371.32	534.04	716.17	698.23	1,153	718.24	Upgrade
Net Cash / Debt Growth	-38.19%	-25.43%	2.57%	-39.46%	60.57%	56.24%	Upgrade
Net Cash Per Share	4.41	7.26	10.24	10.30	18.95	12.69	Upgrade
Working Capital	350.39	451.75	622.69	675.24	1,106	747.72	Upgrade
Book Value Per Share	1.66	3.75	5.04	13.61	18.97	11.55	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).